Announcements Trials
Browse Landscape

Phase

Phase 2 180Phase 1 95Phase 3 43Phase 1/2 33Phase 2/3 12Phase NA 6Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 20NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Serous Adenocarcinoma 1

Interventions

pirtobrutinib 1ibritumomab tiuxetan 1epacadostat 1entinostat 1corticorelin ovine 1amatuximab 1Tetrahydrouridine 1Technetium Tc 99m Medronate 1Stem Cell Transplantation 1Specimen Handling 1Sodium Chloride 1Sodium 1Salpingo-oophorectomy 1Rituximab 1Radiation 1QL1206 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Peripheral Blood Stem Cell Transplantation 1N-(N-((S)-1,3-Dicarboxypropyl)carbamoyl)-4-(18F)fluorobenzyl-L-cysteine 1Midazolam 1Microscopy, Electron 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Ketamine 1Imiquimod 1Hysterectomy 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × NIH × Specimen Handling × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡